Company intelligence / Profile preview
Xenothera
Nantes, Francexenothera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xenothera has advanced a portfolio of glyco-humanized polyclonal antibodies into clinical development. Its lead assets include LIS22 for aggressive lymphomas with orphan drug status from FDA/EMA and currently in Phase I/II trials; XON7 targeting solid tumors also at Phase I/II; and LIS1 being developed both for peripheral T-cell lymphoma and acute graft rejection with a confirmatory pivotal trial planned. The company reports strong safety data so far, with early efficacy signals anticipated as dose escalation continues.[2]
- Therapeutic areas
- Infectious DiseasesImmunologyOncology
- Modalities
- Polyclonal antibodyMonoclonal antibodyBiological productsMulti-specific antibody
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
France2030 program support/funding partners including Pays de la Loire RegionBPI FranceEIC Fund [European Innovation Council]private investors
Beyond the preview
Go deeper on Xenothera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xenothera.